bit.bio CEO Dr Mark Kotter was interviewed by END Points on bit.bio's $103m Series B fundraise and board appointments.
“I’m not going to say this is going to be easy. It’s going to be super hard, but our advantage is that we’re not fighting a biology that is resisting, you know, scale up and consistency.” Mark KotterCo-founder and CEO, bit.bio
“I’m not going to say this is going to be easy. It’s going to be super hard, but our advantage is that we’re not fighting a biology that is resisting, you know, scale up and consistency.”
Read the full Endpoints News article.